Quest Diagnostics Incorporated
Explore Quest Diagnostics
Core profile pages, annual revenue records, and related research hubs for this company.
Quest Diagnostics Incorporated
Explore Quest Diagnostics
Core profile pages, annual revenue records, and related research hubs for this company.
Company History
Founded 1967 in Secaucus, New Jersey, United States
The company added an 85-biomarker Elite Health Profile to its consumer offerings and launched an AI Companion tool that has been engaged approximately 357,000 times since rollout. Quest Diagnostics Incorporated is the world's leading provider of diagnostic information services, founded in 1967 as Metropolitan Pathology Laboratory by Dr. Paul A. Brown in Teaneck, New Jersey. Specimens are transported via a dedicated fleet of ground vehicles and aircraft — including the LabQuest airline operation originally acquired with SmithKline Beecham Clinical Laboratories — to regional and national laboratories for analysis using automated chemistry analyzers, immunoassay systems, molecular diagnostic platforms, next-generation sequencing instruments, and digital pathology systems. Quest Diagnostics traces its origins to a small pathology laboratory founded in 1967 by Dr. Paul A. Brown in Teaneck, New Jersey.
Kenneth W. Freeman was appointed CEO of the newly independent entity, which began trading on the New York Stock Exchange under ticker DGX. In November 2018, Quest launched QuestDirect, its consumer-initiated testing service. Quest launched COVID-19 testing in March 2020 and by July 2020 had performed more than 9.2 million molecular tests and 2.8 million serology tests. In 2025, Quest completed the acquisition of select clinical testing assets from Fresenius Medical Care's Spectra Laboratories and began providing comprehensive dialysis-related laboratory services for Fresenius-operated centers serving approximately 200,000 patients.
Dr. Paul A. Brown was the founder of Metropolitan Pathology Laboratory, Inc. in 1967, the predecessor company to Quest Diagnostics. A practicing pathologist, Brown established the laboratory in Teaneck, New Jersey, to provide clinical pathology and anatomic pathology services to physicians and hospitals in the region. In 1969, the company was renamed MetPath, Inc. Brown led the company's early growth through clinical excellence and physician relationships before Corning Glass Works acquired MetPath in 1982. Brown's founding established the clinical culture and quality focus that would define Quest Diagnostics throughout its evolution from a small regional lab to a global diagnostic enterprise.
Dr. Paul A. Brown founded Metropolitan Pathology Laboratory, Inc. in Teaneck, New Jersey, to provide clinical laboratory services to local physicians and hospitals. The company was renamed MetPath, Inc. in 1969.
Corning Glass Works acquired MetPath and renamed it Corning Clinical Laboratories. This acquisition provided capital and corporate infrastructure for expansion but also meant the laboratory business was a small division within a larger materials science company.
On December 31, 1996, Quest Diagnostics became an independent company through a spin-off from Corning and began trading on the NYSE under ticker DGX. Kenneth W. Freeman was appointed CEO. The spin-off provided strategic flexibility to pursue an acquisition-driven growth strategy.
Quest acquired SmithKline Beecham Clinical Laboratories for approximately $1.3 billion in cash and stock. SBCL had generated $1.6 billion in 1998 revenue and added a national network of laboratories, patient service centers, and a medical sample transport airline. The acquisition doubled Quest's size and established it as the industry leader.
Quest acquired Unilab Corporation for $800 million, significantly expanding its West Coast presence and adding substantial volume in California and surrounding states. The acquisition required divestiture of certain Northern California assets to LabCorp for antitrust clearance.
Quest acquired LabOne, Inc. for $934 million, adding employer drug testing and paramedical testing capabilities that expanded the company's service offerings beyond traditional clinical laboratory testing.
Quest acquired AmeriPath and its subsidiary Specialty Laboratories for approximately $1.23 billion, adding anatomic pathology and cancer diagnostic testing capabilities that complemented Quest's clinical chemistry strengths.
Quest acquired Athena Diagnostics (neurodegenerative disease testing) and Celera Corporation (genomics and sequencing), adding advanced diagnostics capabilities in neurology and genetic testing that would become foundational for future growth initiatives.
Quest acquired Solstas Lab Partners Group for $570 million, expanding its geographic footprint in the Southeastern United States and adding hospital outreach laboratory relationships.
Quest launched QuestDirect, a consumer-initiated testing service that allows patients to order health and wellness lab testing without a physician order in states where permitted. This marked Quest's entry into the direct-to-consumer diagnostic market.
Quest launched COVID-19 testing in March 2020 and by July 2020 had performed more than 9.2 million molecular tests and 2.8 million serology tests. The pandemic created both operational challenges and substantial revenue opportunities for the company.
Quest acquired Blueprint Genetics (Helsinki, Finland) for $108 million, adding genetic testing capabilities for rare diseases and expanding Quest's international genomics expertise.
Jim Davis succeeded Steve Rusckowski as CEO on November 1, 2022, after serving as Executive Vice President of General Diagnostics. Davis brought experience from GE Healthcare, InSightec, and McKinsey & Company. He became Chairman on April 1, 2023.
Quest acquired Haystack Oncology, a minimal residual disease testing company, and the outreach laboratory operations of NewYork-Presbyterian Hospital for $275 million, expanding advanced oncology diagnostics and health system partnerships.
Quest completed the acquisition of LifeLabs from OMERS for approximately CAD $1.35 billion (USD ~$1 billion), adding Canada's leading laboratory diagnostic provider with 6,500+ employees, 8+ million online portal users, and approximately CAD $970 million in annual revenue. LifeLabs continues to operate under its own brand.
Quest completed the acquisition of select clinical testing assets from Fresenius Medical Care's Spectra Laboratories and began providing comprehensive dialysis-related laboratory services for Fresenius-operated centers serving approximately 200,000 patients annually in the United States.
Quest reported record 2025 results with $11.035 billion in revenue (up 11.8%), operating income of $1.556 billion (up 15.6%), and cash from operations of $1.886 billion (up 41.4%). The company raised 2026 guidance and increased its quarterly dividend 7.5% to $0.86 per share.
Quest Diagnostics reports Q1 2026 revenues of $2.895B, 9.0% organic revenue growth, and raises FY2026 net revenue guidance to $11.78B-$11.90B.
Quest acquired SBCL to become the clear industry leader in diagnostic testing. SBCL added a national network of regional laboratories, specialty testing operations, STAT laboratories, patient service centers, and a medical sample transport airline. The acquisition doubled Quest's size.
Quest acquired Unilab to significantly expand its West Coast presence, particularly in California. Unilab was a major regional laboratory operator with strong market positions on the West Coast.
Quest acquired AmeriPath to add anatomic pathology and cancer diagnostic testing capabilities. AmeriPath was a leading provider of anatomic pathology, dermatopathology, and molecular diagnostics.
Quest acquired Solstas to expand its geographic footprint in the Southeastern United States and add hospital outreach laboratory relationships in that region.
Quest acquired Blueprint Genetics (Helsinki, Finland) to add genetic testing capabilities for rare diseases and hereditary conditions, expanding Quest's genomics and precision medicine portfolio.
Quest acquired Haystack Oncology, a minimal residual disease (MRD) testing company, to enter the emerging MRD testing market for solid tumors. MRD testing monitors cancer recurrence by detecting circulating tumor DNA.
Quest acquired LifeLabs from OMERS to establish a dominant position in Canadian laboratory services and expand internationally. LifeLabs is Canada's leading lab provider with 6,500+ employees and 8+ million online portal users.
Quest acquired select clinical testing assets from Fresenius Medical Care's Spectra Laboratories to expand renal-specific testing capabilities for dialysis patients.
Quest Diagnostics traces its origins to 1967, with Paul A. Brown tied to the founding story.
Spin-off from Corning created Quest as an independent national diagnostics company.
Quest Diagnostics expanded by building clinical lab tests, diagnostic panels, specialty testing, employer testing, patient service centers, and lab services, serving patients, physicians, health plans, employers, hospitals, and health systems, and using test menu depth, payer contracts, acquisitions, hospital partnerships, consumer access, and productivity.
This Quest Diagnostics history page covers founding, growth milestones, leadership changes, and modern strategic context.